Toledo-Salinas C, Castaño-Jaramillo LM, Gutiérrez-Hernández A, Scheffler-Mendoza SC

Idioma: Español
Referencias bibliográficas: 29
Paginas: 146-160
Archivo PDF: 272.03 Kb.

RESUMEN

El síndrome multisistémico inflamatorio pediátrico, temporalmente asociado a COVID- 19 (MIS-C/PIMS), es una nueva condición post-infecciosa secundaria a la infección por SARS-CoV2. Se ha caracterizado por una respuesta inflamatoria con afección multisistémica, con involucro de varios mecanismos de daño inmunológico como el incremento exagerado de citocinas y el daño epitelial. El tratamiento inmunomodulador está dirigido a controlar las manifestaciones de hiperinflamación, para estabilizar y prevenir secuelas a largo plazo.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Buonsenso D, Riitano F, Valentini P. Pediatric InflammatoryMultisystem Syndrome Temporally Related WithSARS-CoV-2: Immunological Similarities With AcuteRheumatic Fever and Toxic Shock Syndrome. Front Pediatr. 2020;8(September):1-5.

2. Nakra NA, Blumberg DA, Herrera-Guerra A, LakshminrusimhaS. Multi-System Inflammatory Syndrome in Children(MIS-C /PIMS) Following SARS-CoV-2 Infection: Reviewof Clinical Presentation, Hypothetical Pathogenesis, andProposed Management. Children. 2020;7(7):69.

3. Lawrensia S, Henrina J, Wijaya E, Suciadi LP, Saboe A, CoolCJ. Pediatric Inflammatory Multisystem Syndrome TemporallyAssociated with SARS-CoV-2: a New Challenge amidthe Pandemic. SN Compr Clin Med. 2020;2(11):2077-85.

4. Cheng MH, Zhang S, Porritt RA, Arditi M, Bahar I. An insertionunique to SARS-CoV-2 exhibits superantigenic characterstrengthened by recent mutations. bioRxiv. 2020;1:1-6.

5. Pouletty M, Borocco C, Ouldali N, Caseris M, Basmaci R,Lachaume N, et al. Paediatric multisystem inflammatorysyndrome temporally associated with SARS-CoV-2 mimickingKawasaki disease (Kawa-COVID-19): A multicentrecohort. Ann Rheum Dis. 2020;79(8):999-1006.

6. Felsenstein S, Willis E, Lythgoe H, McCann L, Cleary A,Mahmood K, et al. Presentation, Treatment Response andShort-Term Outcomes in Paediatric Multisystem InflammatorySyndrome Temporally Associated with SARS-CoV-2(PIMS-TS). J Clin Med. 2020;9(10):3293.

7. Ramanathan K, Antognini D, Combes A, Paden M, ZakharyB, Ogino M, et al. Since January 2020 Elsevier has created aCOVID-19 resource centre with free information in Englishand Mandarin on the novel coronavirus COVID- research thatis available on the COVID-19 resource centre - including thisfor unrestricted research re-use a. 2020;(January):19-21.

8. Jonat B, Gorelik M, Boneparth A, Geneslaw AS, ZachariahP, Shah A, et al. Multisystem Inflammatory Syndrome inChildren Associated With Coronavirus Disease 2019 in aChildren’s Hospital in New York City. Pediatr Crit Care Med.2020 Sep 29;Publish Ah:1-14.

9. Elias MD, McCrindle BW, Larios G, Choueiter NF, Dahdah N,Harahsheh AS, et al. Management of Multisystem InflammatorySyndrome in Children Associated With COVID-19:A Survey From the International Kawasaki Disease Registry.CJC Open. 2020;2(6):632-40.

10. Feldstein LR, Rose EB, Horwitz SM, Collins JP, NewhamsMM, Son MBF, et al. Multisystem Inflammatory Syndromein U.S. Children and Adolescents. N Engl J Med. 2020 Jul23;383(4):334-46.

11. Henderson LA, Canna SW, Friedman KG, Gorelik M, LapidusSK, Bassiri H, et al. American College of RheumatologyClinical Guidance for Multisystem Inflammatory Syndromein Children Associated With SARS–CoV-2 and Hyperinflammationin Pediatric COVID-19: Version 1. Vol. 72, Arthritisand Rheumatology. 2020. 1791-1805 p.

12. Ouldali N, Toubiana J, Antona D, Javouhey E, Madhi F, LorrotM, et al. Association of Intravenous ImmunoglobulinsPlus Methylprednisolone vs Immunoglobulins Alone WithCourse of Fever in Multisystem Inflammatory Syndrome inChildren. JAMA. 2021;1-10.

13. Dulek DE, Fuhlbrigge RC, Tribble AC, Connelly JA, Loi MM,El Chebib H, et al. Multidisciplinary Guidance Regardingthe Use of Immunomodulatory Therapies for Acute CoronavirusDisease 2019 in Pediatric Patients. J Pediatric InfectDis Soc. 2020 Dec 31;9(6):716-37.

14. Dove ML, Jaggi P, Kelleman M, Abuali M, Ang JY, BallanW, et al. Multisystem Inflammatory Syndrome in Children:Survey of Protocols for Early Hospital Evaluation and ManagementMatthew. J Pediatr. 2021;229(February):33-40.

15. De Graeff N, Groot N, Ozen S, Eleftheriou D, Avcin T,Bader-Meunier B, et al. European consensus-based recommendationsfor the diagnosis and treatment of Kawasakidisease-the SHARE initiative. Rheumatol (United Kingdom).2019;58(4):672-82.

16. Nguyen AA, Habiballah SB, Platt CD, Geha RS, Chou JS,Mcdonald DR. Immunoglobulins in the treatment ofCOVID-19 infection: Proceed with caution! Clin Immunol.2020 Jul;216:108459. doi: 10.1016/j.clim.2020.108459

17. Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D,Rodriguez L, et al. The Immunology of Multisystem InflammatorySyndrome in Children with COVID-19. Cell.2020;183(4):968-981.e7.

18. Toubiana J, Poirault C, Corsia A, Bajolle F, Fourgeaud J, AngoulvantF, et al. Kawasaki-like multisystem inflammatorysyndrome in children during the covid-19 pandemic inParis, France: prospective observational study. 2020;1–7.

19. Shukur Wasman Smail, Muhammad Saeed, Twana alkasalias,Zhikal Omar Khudhur Delan Ameen Younus, MustafaFahmi Rajab, Wayel Habib Abdulahad, Hafiz Iftikhar Hussain,Kamal Niaz MS. Inflammation, immunity and potentialtarget therapy of SARS-COV-2: a total scale analysis review.Food Chem Toxicol. 2021

20. Sood M, Sharma S, Sood I, Sharma K, Kaushik A. EmergingEvidence on Multisystem Inflammatory Syndrome in ChildrenAssociated with SARS-CoV-2 Infection: a Systematic Reviewwith Meta-analysis. SN Compr Clin Med. 2021;3(1):38-47.

21. Calò Carducci FI, De Ioris MA, Agrati C, Carsetti R, PerrottaD, D’Argenio P, et al. Hyperinflammation in Two SevereAcute Respiratory Syndrome Coronavirus 2-InfectedAdolescents Successfully Treated With the Interleukin-1Inhibitor Anakinra and Glucocorticoids. Front Pediatr.2020;8(November):1-6.

22. Hennon TR, Penque MD, Abdul-Aziz R, Alibrahim OS,McGreevy MB, Prout AJ, et al. COVID-19 associatedMultisystem Inflammatory Syndrome in Children (MIS-C/PIMS) guidelines; a Western New York approach. ProgPediatr Cardiol. 2020 May 23;101232. doi: 10.1016/j.ppedcard.2020.101232.

23. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB.Pharmacologic Treatments for Coronavirus Disease2019 (COVID-19): A Review. JAMA - J Am Med Assoc.2020;323(18):1824-36.

24. Wurth R, Hajdenberg M, Barrera FJ, Shekhar S, GharibOAM, Porter F, et al. Scoping review of COVID-19- relatedsystematic reviews and meta- analyses: can we really haveconfidence in their results ? Postgr Med J Epub. 2021;1-8.

25. Shubhi Kaushik, MBBS1,*, Scott I. Aydin, MD1, 2,*,Kim R. Derespina, MD3, PrernaB.Bansal, MD2, ShannaKowalsky D, Rebecca Trachtman, MD5, JenniferK.Gillen,MD1, Michelle M. Perez, MD3, Sara H. Soshnick, DO,MS3, Edward E. Conway, Jr., MD6, Asher Bercow, MD6,HowardS.Seiden, MD2, Robert H.Pass, MD2, Henry M.Ushay, MD, PhD3, George Ofori-Amanfo, MD1, 2, andShivanand 7, Objective. Multisystem InflammatorySyndrome in Children Associated with Severe AcuteRespiratory Syndrome Coronavirus 2 Infection (MIS-C /PIMS): A Multi-institutional Study from New York City. JPediatr. 2020;224:24-9.

26. Niño-Taravilla C, Espinosa-Vielma YP, Otaola-Arca H,Poli-Harlowe C, Tapia LI, Ortiz-Fritz P. Pediatric inflammatorymultisystem syndrome temporally associatedwith SARS-CoV-2 treated with tocilizumab. Pediatr Rep.2020;12(3):142-8.

27. Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational Use of Tocilizumabin the Treatment of Novel Coronavirus Pneumonia.Clin Drug Investig. 2020 Jun 26;40(6):511-8.

28. McCrindle BW, Rowley AH, Newburger JW, Burns JC, BolgerAF, Gewitz M, et al. Diagnosis, treatment, and long-termmanagement of Kawasaki disease: A scientific statementfor health professionals from the American Heart Association.2017 Apr 25;135(17):e927-e999. doi: 10.1161/CIR.0000000000000484.

29. Abdel-Haq N, Asmar BI, Deza Leon MP, McGrath EJ, AroraHS, Cashen K, et al. SARS-CoV-2-associated multisysteminflammatory syndrome in children: clinical manifestationsand the role of infliximab treatment. Eur J Pediatr. 2021;180(5):1581-1591